Zhitong Finance and Economics APP News, Shandong Xinhua Pharmaceutical (00719) announced that recently, its wholly-owned subsidiary Shandong Zibo Xinda Pharmaceutical Co., Ltd. (hereinafter referred to as "Xinda Pharmaceutical") received the Drug Supplement Application Approval Notice issued by the National Medical Products Administration for Azithromycin Dry Powder Suspension (hereinafter referred to as "this product"), approving this product through generic drug quality and efficacy consistency evaluation.

The announcement stated that Xinda Pharmaceutical's Azithromycin Dry Powder Suspension passed the generic drug quality and efficacy consistency evaluation in December 2024, which will help enrich the company's anti-infective drug product line and enhance the company's overall competitive advantage.